Skip to search formSkip to main contentSkip to account menu

DCC-2036

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

QuinolinesRebastinib Tosylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic…
TPS2666 Background: Rebastinib is a potent, orally administered, kinase switch control inhibitor selectively targeting the tunica… 
2013
2013
Kinase Inhibitor Therapy in CML: It's What's Inside That Counts
The paradigm-shifting clinical success of imatinib in the treatment of chronic myeloid leukemia (CML) established continuous… 
2012
2012
Overcoming Gleevec-resistance by blocking oncogene addiction in malignant hematologic cells
In some types of tumors, malignant cells are highly dependent on the constitutive activation of a certain protein encoded by… 
2012
2012
Non-tyrosine kinase inhibitor-targeting of BCR–ABL expressing cells
Th e introduction in clinical practice of tyrosine kinase inhibitors (TKIs) targeting the oncogenic BCR – ABL protein has had a… 
Review
2011
Review
2011
Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
The 21st century ushered in the dawn of a new era of targeted therapeutics and a dramatic shift in the management of chronic… 
2010
2010
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036
Abstract 3398 Chronic Myeloid Leukemia (CML) treatment was radically modified by the discovery of imatinib (IM), a selective… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)